.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a median follow-up of 11 months, patients along with metastatic stomach tumors that acquired biomarker-matched treatments based upon spreading growth DNA profiling revealed a higher medical benefit than those getting incomparable therapy.